載入中
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
前收盤價
US$14.41
+US$0.41 · +2.93%
盤中時間採用ET。市場資料可能有所延遲。
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
日內區間
目前US$14.41
52週區間
目前US$14.41
盤中時間採用ET。市場資料可能有所延遲。
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
日內區間
目前US$14.41
52週區間
目前US$14.41
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 123.2萬 USD | — | — | — | — |
| 毛利 | −123.2萬 USD | — | — | — | — |
| 研究與開發 | 3083.3萬 USD | 2702萬 USD | 2642.4萬 USD | 2089萬 USD | 1144.7萬 USD |
| 銷售、一般及管理費用 | 1022.3萬 USD | 902.2萬 USD | 925.6萬 USD | 1124.6萬 USD | 234.3萬 USD |
| 營業費用 | 4105.6萬 USD | 3604.2萬 USD | 3568萬 USD | 3213.6萬 USD | 1379萬 USD |
| 利息收入 | 383.7萬 USD | 427.7萬 USD | 483萬 USD | 179萬 USD | 21.1萬 USD |
| 利息支出 | 41.9萬 USD | 30.3萬 USD | 7.5萬 USD | — | — |
| 折舊和攤銷 | 123.2萬 USD | 110.2萬 USD | 107.4萬 USD | 97.9萬 USD | 77.6萬 USD |
| 營業利益 | −4228.8萬 USD | −3604.2萬 USD | −3568萬 USD | −3213.6萬 USD | −1379萬 USD |
| 淨利 | −4262.7萬 USD | −3175萬 USD | −2915.7萬 USD | −3376.2萬 USD | −2727.1萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$18.00
上漲空間 24.91%報告持有此股票曝險的交易所交易基金。
iShares Core MSCI EAFE ETFIEFA659.32萬0.00%1894.71億 USD0.07%US$96.52+0.68%
iShares MSCI EAFE Small-Cap ETFSCZ309.17萬0.02%128.85億 USD0.40%US$83.93+0.82%
ARK Israel Innovative Technology ETFIZRL258.13萬1.98%1.37億 USD0.49%US$28.36+1.61%
iShares MSCI Israel ETFEIS186.62萬0.22%8.6億 USD0.59%US$118.28+0.54%
iShares Core MSCI Total International Stock ETFIXUS87.51萬0.00%586.25億 USD0.07%US$94.99+0.90%
State Street SPDR S&P International Small Cap ETFGWX52.92萬0.06%9.08億 USD0.40%US$45.56+0.93%
Fidelity Nasdaq Composite Index ETFONEQ44.08萬—109.4億 USD0.21%US$107.81+0.63%
Even Herd Long Short ETFEHLS34.98萬0.60%5883.5萬 USD2.62%US$25.4482+0.28%iShares Core MSCI EAFE ETFIEFAiShares MSCI EAFE Small-Cap ETFSCZARK Israel Innovative Technology ETFIZRLiShares MSCI Israel ETFEISiShares Core MSCI Total International Stock ETFIXUSState Street SPDR S&P International Small Cap ETFGWXFidelity Nasdaq Composite Index ETFONEQEven Herd Long Short ETFEHLSAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
